BCL2L13

Across TCGA pan-cancer cohorts, BCL2L13 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated BCL2L13 data layer compared with 25 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher BCL2L13 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated BCL2L13 expression acts as an unfavorable survival marker, although some lineages such as PDAC and UCEC show a favorable association.

LUAD, LSCC, and PDAC are the cancer types where BCL2L13 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	III,IV	0.409	0.941	.010	7	view →
LSCC	OS	Quartile	All	0.765	0.957	.040	7	view →
PDAC	DFS	Quartile	III,IV	0.845	0.315	.042	3	view →
UCEC	OS	Median	All	0.991	0.910	.036	2	view →
HNSC	OS	Tertile	All	0.841	0.631	.033	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

BCL2L13–LUAD (DFS)

Open the LUAD breakdown →